LatAm Autos Stock Quote LAAN - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Previous Close

Open

Last Trade

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share...

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

SALT LAKE CITY, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it completed the sale of its...

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as...

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call...

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer...

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq:...

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...

Myriad Genetics Earns 2024 Great Place To Work® Certification™

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CNDOACondor Energy Ltd	AUD 0.009 (50.00%)	4.3M
ME1Melodiol Global Health Ltd	AUD 0.0015 (50.00%)	1.76M
HVYHeavy Minerals Ltd	AUD 0.14 (47.37%)	680.66k
OVTOvanti Ltd	AUD 0.004 (33.33%)	2.93M
HTMHigh Tech Metals Ltd	AUD 0.16 (33.33%)	36.27k
HZROHazer Group Limited	AUD 0.01 (-60.00%)	50.6k
AD1AD1 Holdings Limited	AUD 0.005 (-44.44%)	5.19M
JAYJayride Group Limited	AUD 0.009 (-30.77%)	500.02k
AEVOAvenira Limited	AUD 0.003 (-25.00%)	5.87k
RADORadiopharm Theranostics Ltd	AUD 0.009 (-25.00%)	863.72k
REDRed 5 Limited	AUD 0.3475 (2.96%)	121.4M
MGRMirvac Group	AUD 1.93 (-8.31%)	69.58M
BRKBrookside Energy Limited	AUD 0.011 (0.00%)	38.41M
AMPAMP Limited	AUD 1.2825 (12.50%)	37.34M
PCLPancontinental Energy NL	AUD 0.014 (-12.50%)	30.5M